The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial
Open accessAbstract
SUMMARY BACKGROUND: In men with a detectable Prostate Specific Antigen (PSA) after prostatectomy for prostate cancer, salvage prostate bed radiotherapy (PBRT) results in about a 70% freedom from progression (FFP) at 5 years (yr). A three-arm randomized trial was designed to determine whether there are incremental gains by adding (i) 4–6 months (mo) of short term androgen deprivation therapy (STADT) to PBRT (64.8–70.2 Gy) and (ii) the combination of STADT and pelvic lymph node radiotherapy (PLNRT; 45 Gy) to PBRT. METHODS: Patients were randomized to PBRT alone (Arm 1), PBRT + STADT (Arm 2), or PLNRT + PBRT + STADT (Arm 3). The FFP primary endpoint included PSA nadir+2, clinical failure, or death from any cause. A planned interim analysis of 1191 patents with minimum potential follow-up time of 5 years applied a Haybittle-Peto (HP) boundary of p < 0.001 (one sided) for comparison of 5-yr FFP rates. FINDINGS: From 2008 – 2015, 1716 eligible patients were enrolled and median follow-up among survivors is 8.2 yr. For the interim analysis population, the HP boundary was exceeded when Arm 1 was compared to Arm 3 (p<0.001). The difference between Arms 2 and 3 did not exceed the boundary (p = 0.002). With additional follow-up beyond the interim analysis (final planned analysis), the 5 yr FFP rates for all 1716 eligible patients were 71%, 81% and 87% for Arms 1, 2 and 3, respectively. Adjusted hazard ratios were 0.50 (97.5% CI: 0.39–0.64) for Arm 3 relative to Arm 1, 0.60 (97.5% CI: 0.47–0.77) for Arm 2 relative to Arm 1, and 0.82 (97.5% CI: 0.63–1.07) for Arm 3 relative to Arm 2. Per protocol criteria, FFP for Arm 3 is superior to Arms 1 and 2. The adjusted HR for distant metastasis was 0.52 (97.5% CI: 0.34–0.81) for Arm 3 vs Arm 1 and 0.71 (97.5% CI: 0.45–1.12) for Arm 3 vs. Arm 2. IMRT was used in 87% of cases. Acute grade 2+ and 3+ adverse events increased significantly from Arm 1 to Arm 2 to Arm 3; however, only significant late grade 2+ blood/bone marrow events were attributable to the use of PLNRT. INTERPRETATION: The results establish the benefit of adding STADT to PBRT and are the first randomized findings to demonstrate that extending salvage radiotherapy to treat the pelvic lymph nodes when combined with STADT results in meaningful reductions in progression. FUNDING: U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Oncology SDMC), UG1CA189867 (NCORP), U24CA180803 (IROC), and P30CA240139 from the National Cancer Institute, and a University of Miami Sylvester Comprehensive Cancer Center Professorship (A.P.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Roach, M., Hanks, G., Thames, H., Schellhammer, P., Shipley, W. U., Sokol, G. H., & Sandler, H. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.04.029 · Cited by 2,749
Self-citationPeto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Thompson, I. M., Tangen, C. M., Paradelo, J., Lucia, M. S., Miller, G., Troyer, D., Messing, E., Forman, J., Chin, J., Swanson, G., et al. (2009) · Journal of Urology · doi:10.1016/j.juro.2008.11.032 · Cited by 1,227
Zubrod, C. G., Schneiderman, M., Frei, E., Brindley, C., Lennard Gold, G., Shnider, B., Oviedo, R., Gorman, J., Jones, R., Jonsson, U., et al. (1960) · Journal of Chronic Diseases · doi:10.1016/0021-9681(60)90137-5 · Cited by 1,034
Stephenson, A. J., Scardino, P. T., Kattan, M. W., Pisansky, T. M., Slawin, K. M., Klein, E. A., Anscher, M. S., Michalski, J. M., Sandler, H. M., Lin, D. W., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.9607 · Cited by 888
Self-citationBolla, M., van Poppel, H., Tombal, B., Vekemans, K., Da Pozzo, L., de Reijke, T. M., Verbaeys, A., Bosset, J.-F., van Velthoven, R., Colombel, M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61253-7 · Cited by 867
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer
Shipley, W. U., Seiferheld, W., Lukka, H. R., Major, P. P., Heney, N. M., Grignon, D. J., Sartor, O., Patel, M. P., Bahary, J.-P., Zietman, A. L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607529 · Cited by 663
Self-citationRoach, M., DeSilvio, M., Lawton, C., Uhl, V., Machtay, M., Seider, M. J., Rotman, M., Jones, C., Asbell, S. O., Valicenti, R. K., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.004 · Cited by 637
Cited by
Parker, C. C., Clarke, N. W., Cook, A. D., Kynaston, H. G., Petersen, P. M., Catton, C., Cross, W., Logue, J., Parulekar, W., Payne, H., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31553-1 · Cited by 410
Tilki, D., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Brunckhorst, O., Darraugh, J., Eberli, D., De Meerleer, G., De Santis, M., Farolfi, A., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.04.010 · Cited by 352
Metadata
- Authors
- Pollack, A., Karrison, T. G., Balogh, A. G., Gomella, L. G., Low, D. A., Bruner, D. W., Wefel, J. S., Martin, A.-G., Michalski, J. M., Angyalfi, S. J., Lukka, H., Faria, S. L., Rodrigues, G. B., Beauchemin, M.-C., Lee, R. J., Seaward, S. A., Allen, A. M., Monitto, D. C., Seiferheld, W., Sartor, O., Feng, F., & Sandler, H. M.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-05
- Volume
- 399
- Issue
- 10338
- Pages
- 1886-1901
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4280514719
- Cited by
- 266
- References
- 35
- FWCI
- 30.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(21)01790-6
- The paper
- Pollack, A., Karrison, T. G., Balogh, A. G., Gomella, L. G., Low, D. A., Bruner, D. W., Wefel, J. S., Martin, A.-G., Michalski, J. M., Angyalfi, S. J., Lukka, H., Faria, S. L., Rodrigues, G. B., Beauchemin, M.-C., Lee, R. J., Seaward, S. A., Allen, A. M., Monitto, D. C., Seiferheld, W., . . . Sandler, H. M. (2022). The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(21)01790-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.